Drug Action
Enoximone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity.
PDF page 229
Loading InternPractice…
Drug reference
Enoximone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity.
PDF page 229
Congestive heart failure where cardiac output reduced and filling pressures increased ▶BY SLOW INTRAVENOUS INJECTION ▶Adult: Initially 0.5–1 mg/kg, rate not exceeding 12.5 mg/minute, then 500 micrograms/kg every 30 minutes until satisfactory response or total of 3 mg/kg given; maintenance, initial dose of up to 3 mg/kg may be repeated every 3–6 hours as required ▶BY INTRAVENOUS INFUSION ▶Adult: Initially 90 micrograms/kg/minute, dose to be given over 10–30 minutes, followed by 5–20 micrograms/kg/minute, dose to be given as either a continuous or intermittent infusion; maximum 24 mg/kg per day
PDF page 229
Heart failure associated with hypertrophic cardiomyopathy, stenotic or obstructive valvular disease or other outlet obstruction
PDF page 229
Sustained haemodynamic benefit has been observed after administration of phosphodiesterase type-3 inhibitors, but there is no evidence of any beneficial effect on survival.
PDF page 230
▶Common or very common Headache. hypotension. insomnia ▶Uncommon Arrhythmias. diarrhoea. dizziness. nausea. vomiting ▶Rare or very rare Chills. fever. fluid retention. myalgia. oliguria. urinary retention
PDF page 229
Manufacturer advises use only if potential benefit outweighs risk.
PDF page 229
Manufacturer advises caution—no information available.
PDF page 229
Dose adjustments Consider dose reduction.
PDF page 230
Monitor blood pressure, heart rate, ECG, central venous pressure, fluid and Cardiovascular system electrolyte status, renal function, platelet count and hepatic enzymes.
PDF page 230
Incompatible with glucose solutions. Use only plastic containers or syringes; crystal formation if glass used. Avoid extravasation. For intravenous infusion (Perfan ®), give continuously or intermittently in Sodium chloride 0.9% or Water for injections; dilute to a concentration of 2.5 mg/mL.
PDF page 230
There can be variation in the licensing of different medicines containing the same drug. Solution for injection EXCIPIENTS: May contain Alcohol, propylene glycol ▶Perfan (Carinopharm GmbH) Enoximone 5 mg per 1 ml Perfan 100mg/20ml solution for injection ampoules | 10 ampoule P s (Hospital only)
PDF page 230
Initially 0.5–1 mg/kg, rate not exceeding
First-line fragment. Read the complete Indications and Dose section above.
PDF page 229
Initially 90 micrograms/kg/minute, dose to be
First-line fragment. Read the complete Indications and Dose section above.
PDF page 229